ROHTO PHARMACEUTICAL CO.,LTD.
Notice Regarding Partial Corrections to “Medium- to Long-Term Growth Strategy 2026”
Earlier from Rohto Pharmaceutical
- Medium- to Long-Term Growth Strategy 2026
- Management Strategy Briefing
- Rohto Pharmaceutical: バージャー病、膠原病により生じる難治性虚血性（非動脈硬化性）下肢潰瘍に対するRE-01細胞治療の第II相医師主導治験を開始
- Notice Regarding the Status of Repurchase of Shares and Completion of Repurchase